Post Date December, 03 2023
Prostate sarcoma is one of the malignant tumors in the prostate, which is different from prostate cancer. Prostate cancer mainly occurs in prostatic epithelial cells, while prostatic sarcoma occurs in prostatic stroma.
The course of prostate sarcoma develops very fast, grows rapidly, and the prognosis is poor. The prognosis of children is particularly poor. After a clear diagnosis, most cases survive for less than one year. Rhabdomyosarcoma is extremely malignant and grows fastest, almost all of them die within one year; Leiomyosarcoma and fibrosarcoma grow slowly and have a slightly better prognosis, with an average survival of 2-3 years.
The development and metastasis of prostate sarcoma in infants and young children are more rapid and widespread than in adults. From the onset of symptoms to death, the average age of children under 10 years old is 3 months, while that of adults is about 1 year. In recent years, the prognosis of rhabdomyosarcoma in children has changed due to surgery, radiotherapy and chemotherapy. For localized lesions, after 2 years of chemotherapy, the tumor-free survival rate of the children was 54%. This progress gives people hope.
At present, the best treatment plan for children is preoperative chemotherapy, surgical resection, postoperative radiotherapy (when there is residual tumor) and periodic preventive chemotherapy. This program has an amazing improvement in the prognosis of children.
For adult patients, it is recommended to use the following regimen: chemotherapy with doxorubicin before operation, followed by prostate and pelvic radiotherapy, followed by radical cystectomy and pelvic lymphadenectomy, and periodic chemotherapy after operation, using doxorubicin and imipramine.
(Intern editor: Huang Junda)
